Overview: Striated Muscle Antibody IFA Dilutions TestIntroduction: The Striated Muscle Antibody IFA Dilutions Test quantifies ASKA to diagnose myasthenia gravis, causing fatigue or drooping eyelids. Following 2023 AAN guidelines, it uses immunofluorescence for high specificity, supporting autoimmune screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in immunology for patients with suspected myasthenia gravis.
Other Names: ASKA IFA Dilutions Assay, Anti-Striated Muscle Titer Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: ASKA dilution testing began in the 1970s with myasthenia gravis research. Immunofluorescence methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Quantifies ASKA to diagnose myasthenia gravis, guides treatment, and evaluates patients with fatigue or drooping eyelids.
Test Parameters: 1. ASKA Presence 2. ASKA Titer
Pretest Condition: No fasting required. Collect serum or saliva. Report history of fatigue, drooping eyelids, or myasthenia symptoms.
Specimen: Serum (SST, 2-5 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document fatigue, drooping eyelids, or history of myasthenia gravis. Include current medications, especially immunosuppressants.
Consent: Written consent required, detailing the tests purpose, myasthenia gravis implications, and risks of sample collection.
Procedural Considerations: Uses indirect immunofluorescence assay (IFA) with serial dilutions to quantify ASKA titers. Results are available in 1-2 days, supporting clinical decisions. Performed in laboratories, often for myasthenia gravis diagnosis.
Factors Affecting Result Accuracy: Sample hemolysis or improper storage can affect results. Cross-reactivity with other autoantibodies may reduce specificity.
Clinical Significance: High ASKA titers confirm myasthenia gravis, guiding immunosuppressive therapy. Negative or low titers may require AChR antibody testing.
Specialist Consultation: Consult a neurologist for result interpretation and treatment planning.
Additional Supporting Tests: AChR antibodies, EMG, or single-fiber EMG to confirm myasthenia gravis diagnosis.
Test Limitations: Non-specific for certain neuromuscular conditions; clinical correlation is needed. Sample quality affects sensitivity.
References: AAN Myasthenia Gravis Guidelines, 2023; Neurology, Verschuuren JJ, 2022.
